ELISA/assay

Human Proteolipid protein ELISA Kit

MBS720678

48-Strip-Wells

470 USD

ELISA Kit

Human Proteolipid protein ELISA Kit

Proteolipid protein

PLP

PLP

Human

This assay has high sensitivity and excellent specificity for detection of PLP. No significant cross-reactivity or interference between PLP and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between PLP and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C

Samples: Serum, plasma, cell culture supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

Neurobiology

Intended Uses: This PLP ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human PLP. This ELISA kit for research use only, not for therapeutic or diagnostic applications!. Principle of the Assay PLP ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-PLP antibody and an PLP-HRP conjugate. The assay sample and buffer are incubated together with PLP-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the PLP concentration since PLP from samples and PLP-HRP conjugate compete for the anti-PLP antibody binding site. Since the number of sites is limited, as more sites are occupied by PLP from the sample, fewer sites are left to bind PLP-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The PLP concentration in each sample is interpolated from this standard curve.

385446

Focal Adhesion Pathway (83067); Focal Adhesion Pathway (478); MAPK Signaling Pathway (83048); MAPK Signaling Pathway (456); Salmonella Infection Pathway (375172); Salmonella Infection Pathway (375149)

This gene encodes a transmembrane proteolipid protein that is the predominant component of myelin. The encoded protein may play a role in the compaction, stabilization, and maintenance of myelin sheaths, as well as in oligodendrocyte development and axonal survival. Mutations in this gene cause Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Alternatively splicing results in multiple transcript variants, including the DM20 splice variant. [provided by RefSeq, Feb 2015]

PLP1: This is the major myelin protein from the central nervous system. It plays an important role in the formation or maintenance of the multilamellar structure of myelin. Defects in PLP1 are the cause of leukodystrophy hypomyelinating type 1 (HLD1); also known as Pelizaeus-Merzbacher disease. HLD1 is an X-linked recessive dysmyelinating disorder of the central nervous system in which myelin is not formed properly. It is characterized clinically by nystagmus, spastic quadriplegia, ataxia, and developmental delay. Defects in PLP1 are the cause of spastic paraplegia X- linked type 2 (SPG2). SPG2 is characterized by spastic gait and hyperreflexia. In some patients, complicating features include nystagmus, dysarthria, sensory disturbance, mental retardation, optic atrophy. Belongs to the myelin proteolipid protein family. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Membrane protein, multi-pass; Membrane protein, integral; Cell surface. Chromosomal Location of Human Ortholog: Xq22. Cellular Component: integral to membrane; plasma membrane; myelin sheath. Molecular Function: structural constituent of myelin sheath; structural molecule activity. Biological Process: integrin-mediated signaling pathway; synaptic transmission; substantia nigra development; myelination in the central nervous system; cell maturation; long-chain fatty acid biosynthetic process; axon ensheathment; inflammatory response; astrocyte development. Disease: Spastic Paraplegia 2, X-linked; Pelizaeus-merzbacher Disease

48-Strip-Wells

470 USD

96-Strip-Wells

675